Teva Pharmaceuticals USA
News and overview for Teva Pharmaceuticals USA
Teva's 'Patient First' Initiative Highlights Struggle Against High Health Care Costs, Reminds Lawmakers of Reform Goals [Press Release]
PRNewswire | 96 days 11 hours 41 minutes ago
Teva's 'Patient First' Initiative...20 /PRNewswire-USNewswire/ --Teva Pharmaceuticals USA, the world's leading generic pharmaceutical...Barrett, Senior Vice President of Teva Pharmaceuticals USA. "The common thread is the hope...
SHIRE PLC - 3rd Quarter Results [Press Release]
PRNewswire | 25 days 10 hours 42 minutes ago
Shire continues to deliver excellent growth from core products
Roche sues Teva over chemotherapy drug
Jerusalem Post, The | 35 days 12 minutes ago
Roche Holding AG, the world's biggest maker of cancer drugs, has accused Teva Pharmaceuticals USA of infringing a patent for its Xeloda oral-chemotherapy drug.
Teva Rebuffed in Patent Cases Over Antibiotic, Herpes Drug
FDAnews | 19 days 4 hours 57 minutes ago
Two federal courts have issued rulings against Teva Pharmaceuticals USA in cases involving its proposed generic versions of Alcon’s antibiotic Vigamox and Novartis Pharmaceuticals’ herpes treatment Famvir. Judge Sue Robinson of the U.S. District Court for the District of Delaware ruled Teva failed to prove that a patent covering Vigamox (moxifloxcin HCl), which is used to treat conjunctivitis, is invalid.
Cephalon announces receipt of a Paragraph IV Certification Notice Letter regarding ANDA
News-Medical.Net | 33 days 19 hours 26 minutes ago
Cephalon, Inc. (Nasdaq: CEPH) today announced receipt of a Paragraph IV Certification Notice Letter on October 20, 2009 regarding an Abbreviated New Drug Application (ANDA) submitted to the U
Cephalon submits receipt of Notice Letter requesting FDA's approval to market and sell NUVIGIL Tablets
News-Medical.Net | 33 days 20 hours 21 minutes ago
Cephalon, Inc. (Nasdaq: CEPH) today announced receipt of a Paragraph IV Certification Notice Letter on October 20, 2009 regarding an Abbreviated New Drug Application (ANDA) submitted to the U
Court Rules Against Teva, Sandoz in Patent Case Over Seroquel
FDAnews | 42 days 5 hours 14 minutes ago
A federal appeals court has upheld a ruling that AstraZeneca didn’t intentionally mislead the PTO to gain a patent on its blockbuster antipsychotic Seroquel.
Shire announces third quarter 2009 financial results
News-Medical.Net | 24 days 20 hours 26 minutes ago
Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to September 30, 2009.
Fertility Guidelines Updated on Number of Embryos Transferred at In Vitro Fertilization
Medscape (free registration) | 35 days 12 hours 4 minutes ago
: The guidelines advise limiting the number of embryos to be transferred to reduce the number of high-risk multiple pregnancies.
Research and Markets: Central Nervous System Therapeutics - A Comprehensive World Market Review of Geographic Coverage and Vertical Market Analysis [Press Release]
Business Wire | 5 days 11 hours 12 minutes ago
Research and Markets (http://www.researchandmarkets.com/research/3cc845/cns_therapeutics) has announced the addition of the "CNS Therapeutics - A World Market Review" report to their offering.
SHIRE PLC - Half Yearly Report [Press Release]
PRNewswire | 95 days 12 hours 10 minutes ago
Half Yearly Report
Reportlinker Adds Autoimmune Disease Therapeutics Report [Press Release]
PRNewswire | 77 days 11 hours 40 minutes ago
...aventis SA , Schering-Plough Corporation, Shire Pharmaceuticals Group plc, Teva Pharmaceuticals Industries Limited, and UCB Pharma. Market...HUMIRA(R) for Psoriasis in the US and EU (USA/Europe) II-71 Contact: Nicolas Bombourg...
Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 [Press Release]
PRNewswire | 91 days 11 hours 40 minutes ago
...copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 works through immune modulation by enhancing...disorders. Founded in 2002 and located in Cambridge, MA USA, the Company is led by an experienced management team...
Prix Galien USA Announces 2009 Final Candidates [Press Release]
PRNewswire | 109 days 18 hours 41 minutes ago
...The 2009 Prix Galien USA will recognize innovative...The 2009 Prix Galien USA ceremony will again be...GLEEVEC(R) -- Novartis Pharmaceuticals, EXELON(R)( )PATCH...and ZETIA(R) -- Teva Neurosciences, AZILECT...Nominees for the Prix Galien USA stand apart from other...
Sun Pharma backs out of Forest patent row
Financial Express (India), The | 27 days 6 hours 57 minutes ago
The largest domestic pharma firm by market value, Sun Pharma, is no more in the running to challenge the patent of Forest Labs over $700-million alzheimer drug, Namenda (adamantane)
Sign up for BIO SmartBrief
Company Overview
| Company: | Teva Pharmaceuticals USA |
|---|---|
| Industry: | Generic Drugs |
| Website: | http://www.tevausa.com/ |
When the pharmacist asks you if a generic equivalent is acceptable, Teva hopes you'll say "yes". Teva Pharmaceuticals USA, the US subsidiary of massive Israeli generic drug maker Teva Pharmaceutical Industries, develops, manufactures, and markets both generic and branded pharmaceuticals. The company is the largest manufacturer of generic drugs in the US; its product roster boasts more than 300 generic equivalents of prescription drugs in a wide variety of therapeutic categories, including cardiovascular, anti-inflammatory, anti-infective, oncology, central nervous system, and dermatological.
Key Numbers
| Sales in U.S. Dollars (mil.) | 0 () |
|---|---|
| One-year % Growth in Sales | 0.0 () |
| Net Income in U.S. Dollars (mil.) | 0 () |
| One-year % Growth in Net Income | 0.0 () |
| Number of Employees | 0 (0) |
| One-year % Growth in Number of Employees | 0.0 (0) |
| Fiscal Year-End |